Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus

Metabolic Syndrome and Related Disorders

Volumn 8, Issue SUPPL. 1, 2010, Pages

  Levy, Philip ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; BIGUANIDE DERIVATIVE; BILE ACID SEQUESTRANT; COLESEVELAM; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; NICOTINIC ACID; PLACEBO; SULFONYLUREA; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE;

CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; DYSPEPSIA; FLATULENCE; HUMAN; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ADULT; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS;

EID: 78650210800     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2010.0087     Document Type: Review

References (21)

1. International Diabetes Federation. IDF Diabetes Atlas. http://atlas.idf-bxl.org/map?id=10. Accessed May 12, 2010.
2. Tanne JH. Endocrinologists say 57 million Americans should be treated for prediabetes. BMJ 2008:337:a998.
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
4. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(Suppl 1):S11-S61.
5. Joslin Diabetes Center and Joslin Clinic Clinical Guidelines for pharmacological management of type 2 diabetes. http://www.joslin.org/docs/ Clinical-Guidelines-for-Pharmacological-Management-of-Type2-Diabetes.pdf. Accessed May 6, 2010.
6. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS. Statement by an Ameri-can Association of Clinical Endocrinologists/American Col-lege of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract 2009;15:540-559.
7. Ong KL, Cheung, Wong IY, Wat NMS, Tan KCB, Lam KSL. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008;18:222-229.
8. Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, Garvey WT, Gavin JR III, Grunberger G, Horton ES, Jellinger PS, Jones KL, Lebovitz H, Levy P, McGuire DK, Moghissi ES, Nesto RW. Diagnosis and management of prediabetes in the continuum of hyper-glycemia: When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. En-docr Pract 2008;14:933-946.
9. Levy P. Bile acid sequestrants as a therapeutic option for glu-cose lowering in type 2 diabetes. Endocr Pract 2008;14:644-647
10. Welchol (colesevelam hydrochloride). Package insert. Par-sippany, N.J. Daiichi Sankyo, Inc., 2009.
11. LRC-CPPT. The Lipid Research Clinics Coronary Prevention Trial. JAMA 1984; 251: 351-364.
12. Brunzell J, Davison M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL, American Diabetes Association; American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: Con-sensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Dia-betes Care 2008;31:811-822.
13. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochlo-ride in subjects with type 2 diabetes. Clin Ther 2007;29:74-83.
14. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in diabetes patients treated with metformin: Glucose and lipid effects. Arch Int Med 2008;168: 1975-1983.
15. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam hydrochloride in patients with type 2 diabetes mellitus with inadequate glycemic control on insulin-based therapy. Arch Int Med 2008;168:1531-1540.
16. Fonseca V, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL-cholesterol in patients with type 2 diabetes inade-quately controlled on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-1484.
17. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant re-duction in low-density lipoprotein and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 di-abetes: a pooled analysis. Metab Syndr Relat Disord 2009;7: 255-258.
18. Rosenstock J, Fonseca VA, Garvey W, Goldberg R, Han-delsman Y, Abby S, Lai Y-L, Jin X, Misir S, Nagendran S, Jones M. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes Endocr Pract 2010;16:629-640.
19. Handelsman Y, Goldberg RB, Garvey TW, Fonxeca VA, Rosenstock J, Jones MR, Lai Y-L, Him X, Misir S, Nagendran S, Abby SL. Colesevelam hydrochloride to treat hypercho-lesterolemia and improve glycemia in prediabetes: A ran-domized prospective study. Endocr Pract 2010;16:617-628.
20. Ratner R for the Diabetes Prevention Group. An update on the Diabetes Prevention Program. Endocr Pract 2006; 12(Suppl 1):20-24.
21. Levy P, Jellinger PS. The potential role of colesevelam in the management of prediabetes and type 2 diabetes mellitus. Postgrad Med 2010;122:1-8.